Equilibrative nucleoside transporter ENT1 inhibitors

Compound of formula (I)

• including any stereochemically isomeric form thereof, wherein -A-B— represents
• wherein n is an integer 0 or 1;
• R13 represents hydroxy or halo;
• R14 represents hydrogen or C1-6alkyl;
• in the bivalent radicals (a-4), (a-5) and (a-6) any of the hydrogen atoms on the same or a different carbon atom may be replaced by halo;
• R1 and R2 are each independently selected from hydrogen, halo or C1-6alkyl;
• R3, R4, R5 and R6 are each independently selected from hydrogen, halo, C1-6alkyl, polyhaloC1-6alkyl, C3-6cycloalkyl, NO2, Cycle1, Cycle2,
• or X—R8 wherein X represents O or NR9,
• wherein R9 is hydrogen, C1-6alkyl or C1-6alkyloxyC1-6alkyl, and
• wherein R8 is hydrogen, C1-6alkyl, C2-6alkenyl, C3-6cycloalkyl, polyhaloC1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, polyhaloC1-6alkylcarbonyl, Cycle2, —(C═O)—(CH2)m-Cycle2, —(C═O)—(CH2)m—CH2—OH, —(C═O)—(CH2)m—CH2—O—C1-4alkyl, or C1-6alkyl substituted with halo, hydroxy, cyano, C3-6cycloalkyl,
• C1-6alkyloxy, aminocarbonyl, phenyl, Cycle1, or Cycle2, or NR11R12 wherein R11 and R12 are each independently selected from hydrogen, C1-6alkyl, C1-6alkylcarbonyl, or C1-6alkyloxycarbonyl;
• m is an integer 0, 1 or 2;
• Cycle1 is selected from
• wherein R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, or C1-6alkyloxycarbonyl;
• and
• Cycle2 is selected from
• wherein R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl or C1-6alkyloxycarbonyl substituted with halo or hydroxy;
• or a pharmaceutically acceptable acid addition salt thereof, or an N-oxide form thereof.